8-K: Moleculin Biotech Announces Positive Interim Data for Annamycin in AML Treatment

Moleculin Biotech reports encouraging preliminary results from its Phase 1B/2 trial of Annamycin in combination with Cytarabine for acute myeloid leukemia (AML), showing significant efficacy and no cardiotoxicity.

Summary

• Moleculin Biotech announced additional positive preliminary data from its Phase 1B/2 clinical trial of Annamycin combined with Cytarabine (AnnAraC) for treating acute myeloid leukemia (AML).
• The data was presented at the European Hematology Association (EHA) 2024 Hybrid Congress and a KOL meeting.
• The trial has enrolled 22 subjects, with 20 having completed efficacy evaluations.
• 45% of evaluable subjects achieved a composite complete remission (CRc), which includes 40% with complete remission (CR) and one with complete remission with incomplete blood count recovery (CRi).
• In second-line treatment, 50% of subjects achieved CR and 60% achieved CRc.
• The median duration of response (mDOR) for subjects achieving CRc is approximately 6 months and increasing.
• The median overall survival (mOS) in second-line subjects is approximately 6 months and increasing.
• 89% of subjects with CRc had poor prognosis cytogenetics and/or mutations.
• Annamycin continues to show no cardiotoxicity.
• The combination was well tolerated, with myelosuppression and infections as the main adverse events.

Sentiment

Score: 8

Explanation: The document presents very positive preliminary clinical data, with strong efficacy signals and no cardiotoxicity. The management's comments are also very optimistic, suggesting a high level of confidence in the drug's potential. However, the data is still preliminary and subject to change, which prevents a perfect score.

Positives

• The trial shows a high rate of composite complete remission (CRc) at 45% in evaluable subjects.
• The combination therapy achieved a 50% CR and 60% CRc rate in second-line AML patients.
• The median duration of response (mDOR) is approximately 6 months and increasing, indicating a sustained benefit.
• The median overall survival (mOS) in second-line patients is approximately 6 months and increasing.
• The treatment showed no cardiotoxicity, a significant advantage over other anthracyclines.
• The majority of patients achieving CRc had poor prognosis cytogenetics and/or mutations, suggesting efficacy in difficult-to-treat cases.

Negatives

• Two subjects discontinued early due to allergic reactions.
• The main adverse events were myelosuppression and infections, which are common with chemotherapy treatments.

Risks

• The data is preliminary and subject to change.
• The trial is still ongoing, and final results may differ from the interim data.
• The treatment's efficacy and safety need to be confirmed in larger, more definitive trials.
• The company is still preparing for an End of Phase 2 meeting with the FDA, indicating that regulatory approval is not yet guaranteed.

Future Outlook

The company is preparing for an End of Phase 2 meeting with the FDA, indicating a move towards potential regulatory approval.

Management Comments

• We continue to be highly encouraged by the positive growing body of preliminary clinical data demonstrated by Annamycin in the treatment of patients with AML, commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin.
• While still preliminary, we believe the efficacy to date including the climbing durability of response demonstrated by AnnAraC in 2nd line patients continues to significantly exceed the performance reported by any drug currently approved for use in 2nd line AML.
• We are incredibly pleased with the progress of the trial and the data and continue to advance our preparations for an End of Phase 2 meeting with FDA.
• These data are exciting, and I believe further underscore the potential of Annamycin to provide patients and physicians with a promising treatment option in AML, concluded Mr. Klemp.

Industry Context

The announcement highlights the potential of Annamycin as a new treatment option for AML, a disease with significant unmet medical needs, particularly in relapsed or refractory cases. The positive data could position Moleculin as a key player in the AML treatment landscape.

Comparison to Industry Standards

• The company states that the efficacy of AnnAraC in 2nd line patients significantly exceeds the performance reported by any drug currently approved for use in 2nd line AML.
• This suggests that Annamycin may offer a superior treatment option compared to existing therapies, such as chemotherapy combinations or targeted therapies like FLT3 inhibitors, which often have lower response rates and shorter durations of response.
• While specific comparisons to individual drugs are not provided, the claim of exceeding current standards indicates a potentially significant advancement in AML treatment.

Stakeholder Impact

• Shareholders may react positively to the encouraging clinical trial results.
• Patients with AML may have a promising new treatment option.
• Physicians may be interested in the potential of Annamycin to improve outcomes for AML patients.

Next Steps

• The company is advancing preparations for an End of Phase 2 meeting with the FDA.
• The company will continue to monitor the trial data and provide updates as they become available.

Key Dates

Keywords

Annamycin, Acute Myeloid Leukemia, AML, Cytarabine, AnnAraC, Clinical Trial, Phase 1B/2, Remission, Cardiotoxicity, Oncology, Hematology